Parkman Healthcare Partners LLC boosted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 29.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 784,376 shares of the biopharmaceutical company's stock after purchasing an additional 179,058 shares during the period. Parkman Healthcare Partners LLC owned approximately 0.26% of Amicus Therapeutics worth $7,389,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock worth $268,112,000 after purchasing an additional 4,497,950 shares in the last quarter. Norges Bank bought a new position in Amicus Therapeutics in the 4th quarter worth about $29,033,000. Orbimed Advisors LLC boosted its stake in shares of Amicus Therapeutics by 300.7% during the fourth quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company's stock valued at $21,528,000 after purchasing an additional 1,715,100 shares in the last quarter. Rock Springs Capital Management LP lifted its position in Amicus Therapeutics by 107.9% during the fourth quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company's stock valued at $24,487,000 after acquiring an additional 1,349,145 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Amicus Therapeutics by 174.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock worth $19,863,000 after buying an additional 1,339,316 shares during the last quarter.
Amicus Therapeutics Stock Performance
Shares of NASDAQ:FOLD traded down $0.02 during trading on Monday, reaching $6.42. The stock had a trading volume of 3,419,014 shares, compared to its average volume of 2,814,843. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of -35.64, a P/E/G ratio of 1.51 and a beta of 0.64. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The stock has a fifty day simple moving average of $7.37 and a two-hundred day simple moving average of $8.88. Amicus Therapeutics, Inc. has a 52 week low of $5.81 and a 52 week high of $12.65.
Analysts Set New Price Targets
Several analysts recently commented on the stock. The Goldman Sachs Group dropped their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. UBS Group lifted their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company lowered their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Finally, StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $16.22.
Check Out Our Latest Stock Report on FOLD
Amicus Therapeutics Profile
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
See Also
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
